Table 2.

Reported cases of ABPA complicated by infection which were treated with mepolizumab.

Age (yr)	Sex	Infectious diseases	Other treatments	Steroid dose	FEV1 (L)	Image change	Time from initial visit to start of administration	Authors (report year) [Ref]
43	F	Cystic fibrosis, NTM	ICS/LABA, OCS, ITCZ, omalizumab	PSL 50mg⇨off	Stable	Stable	11 years	Boyle et al. (2021) [6]
60	F	NTM	LTRA, OCS, ITCZ	PSL 10mg⇨5mg	1.43⇨1.49	Improved	5 years	Tsubouchi et al. (2019) [4]
50	M	MRSA arthritis, CKD	OCS, ITCZ	PSL 30mg⇨off	NA	Improved	40 days	Yanagihara et al. (2020) [17]
63	F	Cystic fibrosis, Pseudomonas aeruginosa, and MRSA carriage	ICS/LABA, LTRA, OCS	PSL 7.5mg⇨ 5mg	Stable	NA	>5 years	Zhang et al. (2020) [19]
34	F	Cystic fibrosis, Pseudomonas aeruginosa, and MRSA carriage	ICS/LABA, LTRA, OCS	PSL⇨off	1.2⇨2	NA	>5 years	Zhang et al. (2020) [19]
24	F	Cystic fibrosis, Pseudomonas aeruginosa, and MRSA carriage	ICS/LABA, LTRA, OCS	PSL 20mg⇨5mg	1.5⇨2	NA	1 year	Zhang et al. (2020) [19]
71	F	NTM, hepatitis B, Pseudomonas aeruginosa, and MRSA carriage	ICS/LABA/LAMA, OCS	PSL 20mg⇨off	0.67⇨1.7	Improved	21 days	Present case

NTM, non-tuberculous mycobacterial disease; CKD, chronic kidney disease; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; MRSA, methicillin-resistant Staphylococcus aureus; OCS, oral corticosteroids; PSL, prednisolone.